The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplasia syndrome developing from Kostmann syndrome

International Journal of Hematology

Volumn 86, Issue 5, 2007, Pages 446-450

  Ebihara, Yasuhiro ^a   Manabe, Atsushi ^b   Tsuruta, Toshihisa ^a   Ishikawa, Kumiko ^a   Hasegawa, Daisuke ^b   Ohtsuka, Yoshitoshi ^a   Kawasaki, Hirohide ^a   Ogami, Kazuo ^a   Wada, Yuka ^a   Kanda, Tadayasu ^c   Tsuji, Kohichiro ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c Kanto Teishin Hospital   (Japan)

Author keywords

Allogeneic stem cell transplantation; Donor leukocyte infusion; Kostmann syndrome; Myelodysplastic syndrome; Refractory pure red blood cell aplasia

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; STEROID;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CASE REPORT; CONTINUOUS INFUSION; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; INFANT; KOSTMANN SYNDROME; MALE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PURE RED CELL ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

CHILD; CYCLOPHOSPHAMIDE; GRAFT SURVIVAL; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKOCYTE TRANSFUSION; LIVING DONORS; MALE; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; MYELOPOIESIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RED-CELL APLASIA, PURE; REMISSION INDUCTION; SYNDROME; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 38349074266     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02984003     Document Type: Article

References (36)

1. Alter BP, Young NS. The bone marrow failure syndromes. In: Nathan DG, Oski FA eds. Hematology of Infancy and Childhood. Vol. 1. Philadelphia, Pa: W. B. Saunders; 1993:216-316.
2. Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol. 2000;111:30-42.
3. Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood. 2000;95:1195-1198.
4. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
5. Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood. 2000;96:1150-1156.
6. Hershko C, Gale RP, Ho W, Fitchen J. ABH antigens and bone marrow transplantation. Br J Haematol. 1980;44:65-73.
7. Klumpp TR, Herman JH, Ulicny J, Emmons RV, Martin ME, Mangan KF. Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38:615-620.
8. Worel N, Kalhs P, Keil F, et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion. 2003;43:1153-1161.
9. Bär BM, Van Dijk BA, Schattenberg A, de Man AJ, Kunst VA, de Witte T. Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow. Bone Marrow Transplant. 1995;16:793-799.
10. Klumpp TR. Immunohematologic complications of bone marrow transplantation. Bone Marrow Transplant. 1991;8:159-170.
11. Takahashi S, Okamoto SI, Shirafuji N, et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant. 1994;13:239-245.
12. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813-3820.
13. Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood. 2004;103:489-491.
14. Ebihara Y, Tsuji K, Lyman SD, et al. Synergistic action of Flt3 and gp130 signalings in human hematopoiesis. Blood. 1997;90:4363-4368.
15. Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol. 2002;20:434-440.
16. Webb DK, Passmore SJ, Hann IM, Harrison G, Wheatley K, Chessells JM. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. Br J Haematol. 2002;117:33-39.
17. Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.
18. Creutzig U, Ritter J, Zimmermann M, et al, for the Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol. 2001;19:2705-2713.
19. Baer MR, Bernstein SH, Brunetto VL, et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood. 1996;87:1484-1494.
20. Budel LM, Touw IP, Delwel R, Löwenberg B. Granulocyte colony-stimulating factor receptors in human acute myelocytic leukemia. Blood. 1989;74:2668-2673.
21. Gmür JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood. 1990;75:290-295.
22. Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:179-184.
23. Braine HG, Sensenbrenner LL, Wright SK, Tutschka PJ, Saral R, Santos GW. Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion. Blood. 1982;60:420-425.
24. Sahovic EA, Flick J, Graham CD, Stuart RK. Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991;302:369-373.
25. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma: European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325:1267-1273.
26. Yang MH, Hsu HC. Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review. Ann Hematol. 2001;80:299-301.
27. Yamaguchi M, Sakai K, Murata R, Ueda M. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30:539-541.
28. Martelli M, Ponchio L, Beguin Y, Meloni G, Mandelli F, Cazzola M. Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica. 1994;79:456-459.
29. Ohashi K, Akiyama H, Takamoto S, Tanikawa S, Sakamaki H, Onozawa Y. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin: Bone Marrow Transplantation Team. Bone Marrow Transplant. 1994;13:335-336.
30. Altés A, López R, Martino R, et al. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders. Bone Marrow Transplant. 2000;26:127-132.
31. Ballester OF, Saba HI, Moscinski LC, Nelson R, Foulis P. Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate. Semin Hematol. 1992;29:106-108.
32. Maschan AA, Skorobogatova EV, Balashov DN, et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant. 2002;30:405-407.
33. +-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant. 1998;22:605-607.
34. Bavaro P, Di Girolamo G, Olioso P, et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol. 1999;104:930-931.
35. Verholen F, Stalder M, Helg C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol. 2004;73:441-446.
36. Musso M, Porretto F, Crescimanno A, Polizzi V, Scalone R. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation. Bone Marrow Transplant. 2004;33:769-771.